MX2022007929A - Coagonistas de triazol grapados de los receptores de glucagon y glp-1. - Google Patents

Coagonistas de triazol grapados de los receptores de glucagon y glp-1.

Info

Publication number
MX2022007929A
MX2022007929A MX2022007929A MX2022007929A MX2022007929A MX 2022007929 A MX2022007929 A MX 2022007929A MX 2022007929 A MX2022007929 A MX 2022007929A MX 2022007929 A MX2022007929 A MX 2022007929A MX 2022007929 A MX2022007929 A MX 2022007929A
Authority
MX
Mexico
Prior art keywords
glp
glucagon
agonists
receptors
stapled
Prior art date
Application number
MX2022007929A
Other languages
English (en)
Inventor
Songnian Lin
Anandan Palani
Qiaolin Deng
Federica Orvieto
Elisabetta Bianchi
Antonello Pessi
Tomi K Sawyer
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2022007929A publication Critical patent/MX2022007929A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Los péptidos grapados de la presente invención, y las sales farmacéuticamente aceptables de los mismos, son los coagonistas de los receptores de glucagon y GLP-1, y pueden ser útiles en el tratamiento, la prevención y la supresión de las enfermedades mediadas por el receptor de glucagon y el receptor de GLP-1, los que incluyen, pero no se limitan a, los trastornos metabólicos tales como la diabetes, la enfermedad del hígado graso no alcohólico (NAFLD, por sus siglas en inglés), la esteatohepatitis no alcohólica (NASH, por sus siglas en inglés) y la obesidad.
MX2022007929A 2019-12-23 2020-12-18 Coagonistas de triazol grapados de los receptores de glucagon y glp-1. MX2022007929A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19425098.1A EP3842061A1 (en) 2019-12-23 2019-12-23 Stapled triazole co-agonists of the glucagon and glp-1 receptors
PCT/US2020/065796 WO2021133644A1 (en) 2019-12-23 2020-12-18 Stapled triazole co-agonists of the glucagon and glp-1 receptors

Publications (1)

Publication Number Publication Date
MX2022007929A true MX2022007929A (es) 2022-09-29

Family

ID=69326342

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007929A MX2022007929A (es) 2019-12-23 2020-12-18 Coagonistas de triazol grapados de los receptores de glucagon y glp-1.

Country Status (10)

Country Link
US (1) US20230063794A1 (es)
EP (2) EP3842061A1 (es)
JP (1) JP2023508349A (es)
KR (1) KR20220119475A (es)
CN (1) CN115226391A (es)
AU (1) AU2020412677A1 (es)
BR (1) BR112022012499A2 (es)
CA (1) CA3162800A1 (es)
MX (1) MX2022007929A (es)
WO (1) WO2021133644A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4392075A1 (en) * 2021-08-27 2024-07-03 Yale University Molecular degraders of extracellular proteins

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
WO1998039342A1 (en) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
PT970095E (pt) 1997-03-07 2004-03-31 Metabasis Therapeutics Inc Novos inibidores benzimidazole de frutose-1,6-bisfosfatase
BR9810378A (pt) 1997-07-01 2000-08-29 Novo Nordisk As Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
CA2343027A1 (en) 1998-09-09 2000-03-16 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
ES2250128T3 (es) 1999-05-17 2006-04-16 Novo Nordisk A/S Antagonistas/agonistas inversos de glucagon.
US6677136B2 (en) * 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
EP1305285B1 (en) 2000-07-25 2007-05-16 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
AU2002240235B2 (en) 2001-01-30 2006-07-06 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
RU2328483C2 (ru) 2002-08-29 2008-07-10 Мерк Энд Ко., Инк. Индолы, обладающие противодиабетической активностью
CA2495915A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
AU2004207444B2 (en) 2003-01-17 2008-07-31 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
US8546326B2 (en) * 2005-06-06 2013-10-01 Camurus Ab Glp-1 analogue formulations
AU2006258841B2 (en) 2005-06-13 2012-05-03 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
WO2008010017A1 (en) 2006-07-19 2008-01-24 Freescale Semiconductor, Inc. Method and apparatus for designing an integrated circuit
CN101743616B (zh) 2007-06-28 2012-02-22 株式会社半导体能源研究所 半导体装置的制造方法
AU2008267724A1 (en) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd Substituted fused pyrimidines as antagonists of GPR105 activity
EP2178537A4 (en) 2007-07-19 2011-08-17 Merck Sharp & Dohme BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS
WO2009042053A2 (en) 2007-09-21 2009-04-02 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof
JP5775450B2 (ja) * 2008-06-17 2015-09-09 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
KR20140043793A (ko) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-작용물질
US20140221283A1 (en) 2011-06-22 2014-08-07 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
CA2935026C (en) * 2014-01-15 2018-11-13 Fyziologicky Ustav Akademie Ved Cr, V.V.I. Lipidated prolactin-releasing peptides for lowering blood glucose
JP6581656B2 (ja) 2014-10-24 2019-09-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． グルカゴンおよびｇｌｐ−１受容体のコアゴニスト
WO2017074798A2 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Long-acting co-agonists of the glucagon and glp-1 receptors
WO2017189342A1 (en) * 2016-04-26 2017-11-02 Merck Sharp & Dohme Corp. Insulin dimer-incretin conjugates
AU2018338184B2 (en) 2017-09-25 2023-04-13 Merck Sharp & Dohme Llc Long-acting co-agonists of the glucagon and GLP-1 receptors
CN109836488B (zh) * 2017-11-24 2022-08-23 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物

Also Published As

Publication number Publication date
BR112022012499A2 (pt) 2022-09-06
EP4081243A4 (en) 2024-01-10
EP4081243A1 (en) 2022-11-02
US20230063794A1 (en) 2023-03-02
KR20220119475A (ko) 2022-08-29
CA3162800A1 (en) 2021-07-01
EP3842061A1 (en) 2021-06-30
WO2021133644A1 (en) 2021-07-01
AU2020412677A1 (en) 2022-07-14
JP2023508349A (ja) 2023-03-02
CN115226391A (zh) 2022-10-21

Similar Documents

Publication Publication Date Title
PH12017500761A1 (en) Co-agonists of glucagon and glp-1 receptors
PH12020551025A1 (en) Incretin analogs and uses thereof
PH12020551024A1 (en) Incretin analogs and uses thereof
PH12021551165A1 (en) Glp-1r agonists and uses thereof
MX2021012492A (es) Agonistas de glp-1r y usos de los mismos.
MY190210A (en) Glucagon and glp-1 co-agonist compounds
MX2015010935A (es) Compuestos biciclicos antidiabeticos.
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
MX2016015182A (es) Compuestos triciclicos antidiabeticos.
MX366175B (es) Composiciones fosfolipidicas terapeuticas concentradas.
PH12019550226A1 (en) Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
MX2021008010A (es) Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).
EA202091464A1 (ru) Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита
MX2023008330A (es) Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
MX2022007929A (es) Coagonistas de triazol grapados de los receptores de glucagon y glp-1.
MX2021002655A (es) Terapia de combinacion para el tratamiento de enfermedad hepatica.
WO2016168388A3 (en) Therapies for obesity, diabetes and related indications
JOP20220153A1 (ar) نظائر الإنكرتين واستخداماتها
MX2022007928A (es) Co-agonistas de olefina engrapados de los receptores de glucagon y glp-1.
MX2022007926A (es) Coagonistas lactamicos grapados de los receptores de glucagon y glp-1.
MX2022013230A (es) Analogos de glucagon como agonistas de accion prolongada del receptor de glp-1/glucagon para usarse en el tratamiento de enfermedad del higado graso y esteatohepatitis.
MX2022000388A (es) Terapia de combinacion de agonista de gpr119 e inhibidores de dpp-4.
WO2015051234A3 (en) Tweak antagonists for treating lupus nephritis and muscle atrophy